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Clinical tuberculosis (TB), whether noncavitary or cavitary, is the late stage of a chronic disease process,
since Mycobacterium tuberculosis is a slowly growing organism. Our studies have shown that the profiles of
antigenic proteins expressed by the in vivo bacteria that elicit antibodies differ in cavitary and noncavitary TB
(K. Samanich, J. T. Belisle, and S. Laal, Infect. Immun. 69:4600–4609, 2001). To gain insight into antigenic
proteins expressed during incipient, subclinical TB, an expression library of M. tuberculosis genomic DNA was
screened with sera obtained during subclinical TB from guinea pigs infected with aerosols of M. tuberculosis
H37Rv. One of the proteins recognized by antibodies elicited during subclinical TB infection of guinea pigs is
the 309-kDa PPE55 (Rv3347c) protein. Genomic hybridization studies suggest that the PPE55 gene is specific
to the M. tuberculosis complex and is present in a majority of clinical isolates tested. Antibodies to the
C-terminal, 100-kDa fragment of PPE55 (PPE-C) were detectable in sera from 29/30 (97%) human immu-
nodeficiency virus-negative/TB-positive (HIV TB) patients and 17/24 (71%) HIV TB patients tested but
not in sera from purified-protein derivative-positive healthy controls, suggesting that the in vivo expression of
PPE55 protein correlates with active M. tuberculosis infection. Anti-PPE-C antibodies were also detected in
retrospective sera obtained months prior to manifestation of clinical TB from 17/21 (81%) HIV TB indi-
viduals tested, providing evidence that the protein is expressed during incipient, subclinical TB in HIV-infected
humans. Thus, PPE55 is a highly immunogenic protein that may be useful for differentiating between latent TB
and incipient, subclinical TB.
Approximately 5 to 10% of individuals who get infected with
Mycobacterium tuberculosis progress to clinical tuberculosis
(TB), whereas the remaining individuals develop a latent in-
fection with the organism. Another 5 to 10% of these latently
infected individuals reactivate their infection and progress to
clinical TB during subsequent years/decades. In either case,
active infection with M. tuberculosis is identified only when
progression to bacteriologically detectable disease occurs.
Thus, clinical TB, whether noncavitary paucibacillary or cavi-
tary multibacillary disease, represents the late stages of a
chronic disease process.
Our studies of humoral immune responses elicited by M.
tuberculosis at different stages of infection and disease progres-
sion have shown that the profile of antigenic proteins ex-
pressed by the in vivo bacteria that elicit antibodies correlates
with the stage of the infection (21–23, 35–37, 45). Thus, puri-
fied-protein derivative-positive (PPD) healthy individuals
have antibodies to only a small subset (4–6) of the 100 cul-
ture filtrate proteins (CFP) of M. tuberculosis. In contrast,
patients with noncavitary paucibacillary TB have antibodies
directed against 10 to 12 additional CFP antigens (35). As
the disease progresses to the development of cavitary lesions,
besides the presence of antibodies to the above-mentioned
antigens, antibodies to an additional 10 to 12 antigens ap-
pear. These results provide evidence that as M. tuberculosis
adapts to different in vivo environments, the profile of anti-
genic proteins that are expressed changes. Evidence for adap-
tation by M. tuberculosis to different environmental conditions
by altering gene/protein expression has also come from several
other labs (3, 11, 12, 29, 32, 41, 42, 47, 49).
M. tuberculosis is a slowly growing organism, and it takes
weeks to months for the infection to progress to primary clin-
ical TB. The time that elapses between the initiation of reac-
tivation of latent infection and the manifestation of clinical TB
is not known. The goal of the current studies was to identify
antigenic proteins that are expressed during the asymptomatic,
subclinical stages of infection when the in vivo M. tuberculosis
bacilli replicate actively but the infection has not progressed to
clinically identifiable disease (incipient, subclinical TB). Insight
into these antigenic proteins will aid understanding of the
host-pathogen interactions that lead to the progression of in-
fection to clinical disease, and modulation of these host-patho-
gen interactions could potentially alter the outcome of infec-
tion. Moreover, antigenic proteins expressed during subclinical
stages of active infection would also be useful for devising
diagnostic markers that can differentiate between truly latent
TB that is unlikely to progress to clinical disease and incipient,
subclinical TB.
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Humans with incipient, subclinical TB are asymptomatic and
cannot be identified, since neither PPD reactivity nor any other
markers of infection (ESAT-6, CFP10) can differentiate be-
tween individuals who have latent TB and those who have
incipient, subclinical TB (21, 24). To determine the profile of
antigenic proteins expressed by M. tuberculosis during incipi-
ent, subclinical TB, we used sera obtained from guinea pigs
that were infected with low-dose aerosols of M. tuberculosis
H37Rv and bled prior to progression of the infection to clinical
TB. These subclinical-TB sera were used for immunoscreening
of an expression library of genomic DNA of M. tuberculosis. Of
the several clones that were identified, two clones expressed
different portions of the same PPE55 (Rv3347c) protein. The
PPE protein family was first identified when the genome of M.
tuberculosis was sequenced, and the role of these proteins in
the pathogenesis of TB is a subject of intense investigation (7).
Some PPE proteins have been reported to elicit strong hu-
moral and cellular responses in M. tuberculosis-infected ani-
mals and humans (5, 8, 9, 31, 46). In the current studies, we
provide evidence that the PPE55 gene is specific to the M.
tuberculosis complex and is present in a majority of the clinical
isolates tested. The C-terminal region of the PPE55 protein
was expressed in Escherichia coli and used to evaluate immune
recognition by antibodies in sera from TB patients at different
stages of the disease. Results provide evidence that PPE55 is a
strongly immunogenic protein whose in vivo expression corre-
lates with active infection with M. tuberculosis in humans with
both incipient, subclinical TB and active clinical TB. Thus, the
presence of anti-PPE55 antibodies can serve to distinguish
between latent and active M. tuberculosis infection.
MATERIALS AND METHODS
Serum samples from guinea pigs. Twenty-nine randomly bred, Hartley strain
guinea pigs (350 to 500 g) were infected with 4 to 10 CFU airborne, virulent M.
tuberculosis H37Rv in an aerosol infection chamber (27). Guinea pigs infected in
this manner develop clinical signs of TB (weight loss and respiratory distress)
around 8 to 10 weeks postinfection (p.i.) and die of TB by 14 to 18 weeks p.i. (27).
To obtain sera representing the subclinical stage of active infection, groups of
infected animals were euthanized and bled at 1 to 6 weeks p.i. Sera were also
obtained from infected animals bled at 10 and 15 weeks p.i. to obtain specimens
from animals with clinical TB. Since guinea pigs are exquisitely sensitive to
infection with M. tuberculosis and do not develop latent infection, sera from three
uninfected guinea pigs were included as specimens from animals who do not
harbor actively replicating M. tuberculosis.
Serum samples from humans. Serum samples obtained with informed consent
from 132 individuals were included in these studies. These individuals can be
categorized into the following groups.
(i) PPD healthy individuals. Twenty-two of the 29 PPD healthy individuals
were recent immigrants from areas where TB is endemic (India, China, Cam-
eroon, and eastern Europe) who were working at the Manhattan Veterans
Affairs Medical Center (VAMC) in New York, N.Y. A vast majority of these
individuals were vaccinated with Mycobacterium bovis BCG, and it is likely that
a high proportion would also have been exposed to M. tuberculosis. Seven U.S.
citizens who were PPD were most likely latently infected with M. tuberculosis.
(ii) PPD individuals. The 10 PPD individuals were healthy individuals
working at the VAMC. These individuals were unlikely to be infected with M.
tuberculosis.
(iii) HIV TB individuals. The 20 human immunodeficiency virus-positive/
TB-negative (HIV TB) individuals were HIV-infected individuals from the
VAMC with no history or clinical symptoms of TB. Their PPD statuses were not
known. All individuals except one were on antiretroviral therapy.
(iv) HIV TB patients. The 24 HIV TB patients were acid-fast-bacillus
(AFB) sputum smear-positive or smear-negative, culture-positive patients from
the VAMC. These patients were bled at the time of clinical diagnosis of TB.
These sera are considered equivalent to sera obtained from animals that were
bled at 10 and 15 weeks p.i.
(v) HIV TB patients with subclinical TB. Twenty-one of the 24 HIV TB
patients described above were HIV patients who were routinely monitored for
their T-cell profiles during the late 1980s and early 1990s (prior to highly active
antiretroviral therapy) and who developed TB during the course of progression
of HIV infection. Thus, sera that were obtained from these patients prior to
progression to clinical TB (HIV subclinical TB) were available. These retro-
spective sera are considered the equivalent of sera obtained from guinea pigs
bled during weeks 1 to 6 p.i. (22).
(vi) HIV TB patients. The 30 HIV TB patients were AFB smear-positive
TB patients with cavitary lesions, and sera were obtained from the Lala Ram
Sarup Institute of Tuberculosis and Respiratory Diseases (LRSITRD), New
Delhi, India. These sera are considered to be equivalent to sera obtained at
weeks 10 and 15 p.i. from guinea pigs.
(vii) Household contacts of smear-positive TB patients. The 19 household
contacts of smear-positive TB patients (HIV TB HH contacts) were clinically
asymptomatic household contacts of infectious, untreated, smear-positive TB
patients, and these sera were also obtained from the LRSITRD, New Delhi. The
PPD statuses of these individuals were not known. However, despite being
asymptomatic, because of their frequent exposure to smear-positive family mem-
bers, a small proportion of these individuals (estimated to be from 6 to 29% in
different studies) are expected to have an active infection (6, 10, 14, 51).
M. tuberculosis H37Rv antigen preparations. The M. tuberculosis H37Rv anti-
gen preparations used were obtained from John T. Belisle under the NIH/
NIAID TB Research Material and Vaccine Testing contract (Colorado State
University, Fort Collins) and included (i) lipoarabinomannan-free CFP (LF-
CFP), (ii) sodium dodecyl sulfate-derived cell wall proteins (SDS-CW), (iii) cell
wall fractions (CW), (iv) whole M. tuberculosis bacterial lysates, (v) purified
native 45-kDa (MPT32) proteins, and (vi) purified native 38-kDa (PstS) proteins.
The preparation of these proteins has been described earlier (23, 37).
Immunoscreening of the M. tuberculosis gt11 library and identification of
recombinant clones. The gt11 expression library of M. tuberculosis H37Rv DNA
(World Health Organization) was screened with a serum pool prepared from
guinea pigs bled at 1 to 6 weeks p.i. (38, 52). Serum from one animal was
randomly selected from each time point for inclusion into the pool. DNA se-
quencing of the M. tuberculosis inserts, analysis of sequences, and identification
of the M. tuberculosis proteins expressed in the positive recombinant gt11 clones
were performed as described earlier (45).
Mycobacterial-DNA isolation and Southern blot analysis. Genomic DNA
from M. tuberculosis H37Rv, M. tuberculosis H37Ra, M. tuberculosis Erdman, and
clinical isolates CSU 11, CSU 17, CSU 19, CSU 22, CSU 25, CSU 26, and CSU
27 were obtained from John T. Belisle. Stock cultures of M. bovis, M. bovis BCG,
M. africanum, M. microti, M. smegmatis, M. vaccae, M. phlei, M. chelonae, and M.
xenopi were obtained from the ATCC (American Type Culture Collection, Ma-
nassas, VA) and grown in Middlebrook 7H9 broth (Difco) supplemented with
0.2% glycerol, 0.05% Tween 80, and 1 ADS (0.5% bovine serum albumin
[BSA], fraction V [Sigma, St. Louis, MO]; 0.2% dextrose; and 0.85% NaCl). The
genomic-tip system (QIAGEN Inc., Valencia, CA) was used to extract genomic
DNA from mid-log-phase bacterial cultures per the manufacturer’s protocols.
One microgram of each genomic DNA was digested with SacI, the fragments
were separated on a 0.8% agarose gel, and the Southern blots that were prepared
were probed with a 480-bp digoxigenin (DIG)-labeled probe amplified with
primers PPE1 (5-GTGTTGTACACGCCCGAGATGCCC-3) and PPE2 (5-G
AACCCGACGACACTGCACTTCCC-3) from M. tuberculosis H37Rv genomic
DNA (DIG probe synthesis kit; Roche Diagnostic Corporation, IN). These
primers allow the amplification of a 480-bp fragment only from the PPE55 gene.
Hybridization and detection were performed by using a DIG standard hybrid-
ization buffer and a chemiluminescence detection system according to the man-
ufacturer’s protocols (Roche).
Expression and purification of recombinant M. tuberculosis PPE55 protein. A
3,072-bp fragment encoding the C-terminal 978 amino acids (aa) of PPE55
(designated PPE-C) was amplified from M. tuberculosis H37Rv genomic DNA
with primers 5-CTTCCATATGGGCAGCATCAACACC-3 (forward primer)
and 5-TGCCCTCGAGGACTTCTTATTTCATAC-3 (reverse primer) con-
taining NdeI and XhoI sites (underlined), respectively. The amplified PPE-C
fragment was cloned into a pCR BluntII TOPO vector (Invitrogen Corporation,
Carlsbad, CA) and verified by sequencing. Subsequently, the PPE-C fragment
was cloned at NdeI-XhoI sites into expression vector pET-14b (Novagen Inc.,
Madison, WI) to generate pET14b-PPE-C. After verification of the reading
frame, the recombinant plasmid pET14b-PPE-C was transformed into E. coli
expression host Rosetta (DE3), and a single colony containing the recombinant
plasmid was used as the source of the recombinant PPE-C protein. Uninduced E.
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coli harboring the recombinant plasmid and induced cultures of E. coli contain-
ing the pET14b vector alone were used as controls. The recombinant protein was
purified from lysates of induced E. coli cells by using Ni-nitrilotriacetic acid
agarose affinity chromatography according to the manufacturer’s protocols
(QIAGEN).
Synthetic peptides. The amino acid sequence of the PPE-C protein was sub-
jected to analysis for regions of high antigenicity by computer algorithms that
predict antigenic regions based on probability of surface exposure, local hydro-
philicity, beta-turns, etc. (PCGENE [Intelligenetics, Inc., Mountain View, CA];
EMBOSS Antigenic [EMBO software]; Epitope Informatics [Epitope Informat-
ics Ltd., Durham, United Kingdom]; Peptool [Life Sciences Software Resources,
Inc.]) (16, 17, 20, 33). The prediction of antigenic regions and synthesis of
corresponding peptides tagged with an N-terminal biotin residue were per-
formed by Global Peptide Services, Fort Collins, CO.
Western blot analysis. Reactivity of guinea pig or human sera with LFCFP or
lysates of E. coli expressing His-tagged PPE-C protein or purified His-PPE-C
protein was tested by Western blotting as described previously (44). Briefly,
LFCFP, lysates of E. coli expressing the PPE-C protein, appropriate control
lysates, or purified PPE-C protein was fractionated on 10% SDS-polyacrylamide
gels under reducing conditions, and the Western blots were probed with anti-His
monoclonal antibody (MAb) or E. coli lysate-absorbed sera from guinea pigs or
humans (1:100) (23). The blots of purified PPE-C protein were probed with
unabsorbed sera from PPD healthy individuals or smear-positive TB patients
(1:100). The detection system was comprised of alkaline phosphatase-conjugated
anti-mouse immunoglobulin G (IgG), anti-guinea pig IgG, or anti-human IgG
(Zymed Laboratories, Inc., CA) and BCIP (5-bromo-4-chloro-3-indolylphos-
phate)-nitroblue tetrazolium (KPL, Inc., Gaithersburg, MD) as the substrate.
ELISA withM. tuberculosis antigens and peptides. Enzyme-linked immunosor-
bent assays (ELISA) were optimized to detect the reactivities of sera from
infected guinea pigs with M. tuberculosis antigens (37). LFCFP, SDS-CW, CW,
and M. tuberculosis cell lysates were coated at 5 g/ml, and purified MPT32 and
38-kDa antigens were coated at 2 g/ml (50 l/well). The guinea pig sera were
absorbed against E. coli lysates to remove cross-reactive antibodies and tested for
reactivity with these antigens at a 1:100 dilution (23, 37).
For assessment of the reactivity of the PPE-C protein with sera from TB
patients and control individuals, purified recombinant PPE-C was coated at 10
g/ml (50 l/well) overnight at 4°C. The plates were washed three times with
phosphate-buffered saline (PBS) containing 0.1% Tween 20, and the wells were
blocked with 1% BSA-PBS containing 0.1% Tween 20 (blocking buffer) for 2 h
at 37°C. After three washes, the antigen-coated wells were exposed to sera (1:50
in 0.1 blocking buffer) for 30 min at 37°C, followed by exposure to a mixture of
diluted alkaline phosphatase-conjugated protein A (1:2,000; Sigma) and goat
anti-human IgA (1:1,000; Sigma) for 30 min at 37°C. The wells were washed eight
times with Tris-buffered saline (50 mM Tris, 150 mM NaCl), and the color was
developed using an Invitrogen amplification system (Invitrogen). The mean
optical density at 490 nm (OD490) obtained with sera from PPD and PPD
individuals, plus 3 standard deviations (SD), was used as the cutoff to determine
positive responses in the patients.
For assessing the reactivities of biotinylated peptides with sera from TB pa-
tients and controls, a mixture of 50 l of peptide (1 g/ml) diluted in blocking
buffer (7.5% fetal bovine serum [HyClone, Utah] and 2.5% BSA in PBS) and 50
l of sera (1:10 in 0.1 blocking buffer) was added to wells of streptavidin-coated
ELISA plates (Roche) and incubated for 1 h at 37°C. The peptide-antibody
complexes bound to the wells were detected as described above.
Statistical analysis. The Fisher test was used to determine the correlation
between the presence of antibodies to peptides PPE-C1 and PPE-C2 in the
HIV TB, HIV TB, and subclinical-TB patient groups.
Bioinformatic analysis. DNA and protein sequence similarities were per-
formed by using the BLAST program on the National Center for Biotechnology
Information (NCBI) website. BLAST searches with genome databases of M.
tuberculosis H37Rv, M. tuberculosis CDC1551, M. tuberculosis 210, M. bovis, M.
leprae, M. avium 104, M. avium subsp. paratuberculosis, M. marinum, and M.
smegmatis were also performed using the genomic BLAST program on the NCBI
website. The BLAST search with the M. ulcerans genome database was done on
the BuruList World Wide Web server. Prediction of theoretical molecular weight
and amino acid composition by ProtParam, determination of transmembrane
helices by TMpred, identification of repetitive sequences by statistical analyses of
protein sequences, signal peptide assessment by SignalP (version 2.0) trained on
gram-positive bacteria, determination of glycosylation sites by NetOGlyc 2.0, and
Kyte & Doolittle hydropathicity plotting by ProtScale were carried out with the
respective softwares available on the ExPASy Proteomics server.
RESULTS
Anti-M. tuberculosis humoral responses in aerosol-infected
guinea pigs. Previous studies from our lab have shown that
sera from PPD healthy individuals have antibodies to a dou-
blet of antigens at 32 to 33 kDa and another protein band at
65 to 67 kDa in the LFCFP (35). The same three antigens are
also recognized by sera from PPD healthy individuals (35).
Mapping of these antigens identified the doublet to be the
antigen 85 complex (35). Sera from cavitary-TB and noncavi-
tary-TB patients have antibodies to these three cross-reactive
antigens and several additional antigens in the LFCFP ranging
from 26 to 115 kDa (35). To validate the use of guinea pigs
for studies of humoral immune responses to M. tuberculosis
antigens, reactivities of LFCFP with sera from two guinea pigs
with TB (15 weeks p.i.) and from four randomly chosen TB
patients were evaluated by Western blotting. The sera from
uninfected guinea pigs and PPD healthy individuals, neither
of whom would have had replicating M. tuberculosis, were
included as controls. The sera from the uninfected animals and
PPD humans showed reactivity with the doublet of M. tuber-
culosis antigens at32 to 33 kDa and a single band at68 kDa
(Fig. 1A, lanes 2, 3, 10, and 11). In contrast, sera from guinea
pigs with TB showed reactivity with several additional bands
ranging from 26 kDa to 115 kDa (Fig. 1A, lanes 4 and 5).
The guinea pigs with TB and the human TB patients had
antibodies to similar profiles of proteins in the LFCFP (Fig.
1A, lanes 6 to 9, and additional patients in reference 35). As
reported earlier with sera from different TB patients, some
variation in the intensities of reactivity with individual proteins
between the sera from the two animals and the four human
patients was observed (35).
M. tuberculosis antigens recognized during subclinical TB in
infected guinea pigs. After confirmation that PPD/PPD
healthy individuals and uninfected guinea pigs (lacking actively
replicating bacteria) recognize similar sets of LFCFP antigens
and that TB patients and tuberculous guinea pigs recognize
similar profiles of antigens, the antigen profile recognized by
antibodies obtained from the guinea pigs during subclinical TB
(1 to 6 weeks p.i.) was investigated. Sera from animals with TB
(10 and 15 weeks p.i.) were included as positive controls, and
sera from uninfected animals were included as negative con-
trols (Fig. 1B). Sera obtained 1 to 6 weeks p.i. reacted primarily
with the doublet at 32 to 33 kDa, and some sera also recog-
nized proteins of 68 kDa or, weakly, proteins of 29 kDa (Fig.
1B, lanes 1 to 24). In contrast, sera from two out of three
animals bled at 10 weeks p.i. and from both animals bled at 15
weeks p.i. recognized multiple antigens in the LFCFP (Fig. 1B,
lanes 26 to 29). The reactivities of all of these sera with cell
lysate and cell wall antigens of M. tuberculosis and with the
purified 38-kDa (PstS) and 45-kDa (MPT32) proteins, which
are known to be associated with advanced clinical TB in hu-
mans, were also tested by ELISA (4, 35). Using the mean OD
plus 3 SD obtained with the sera from the three uninfected
guinea pigs as the cutoff, except for one animal bled at 6 weeks
p.i., reactivity with the mycobacterial antigens was observed
only with sera from animals bled at 10 or 15 weeks p.i. (Fig.
1B). These results suggested that strong antibody responses to
antigens present in these mycobacterial fractions and to the
purified 38- and 45-kDa antigens are elicited only during the
5006 SINGH ET AL. INFECT. IMMUN.
 o
n
 Septem
ber 21, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
advanced stages of active infection, when clinical TB manifests.
During subclinical TB, either the antibody titers are too low or
the target antigens are absent or quantitatively underrepre-
sented in the antigen preparations being used.
Screening of the M. tuberculosis gt11 library and charac-
terization of recombinant clones. To explore the possibility
that antibodies are present in subclinical-TB sera but that the
antigens that elicit these antibodies are poorly represented in
our antigen preparations, a subclinical-TB serum pool contain-
ing one serum from each time point (1 to 6 weeks p.i.) was used
for immunoscreening of the gt11 expression library of M.
tuberculosis H37Rv. Nine strongly reactive recombinant clones
were obtained. This study describes the results obtained with
two of the nine clones (clones 1 and 2).
DNA sequence and restriction analyses revealed that the
peptides expressed in clones 1 and 2 represent aa 2400 to 2639
and 3104 to 3157, respectively, in the C-terminal half of the
same PPE55 (Rv3347c) gene product (Fig. 2). PPE55 is a
3,157-aa (309-kDa) protein which belongs to the MPTR (ma-
jor polymorphic tandem repeat) subfamily of the PPE family of
M. tuberculosis proteins (7). PPE55 contains 47 tandem copies
of the motif Asn-X-Gly-X-Gly-Asn-X-Gly (perfect repeats)
and 49 tandem copies of the same motif with alterations at
positions 5 and 6 (imperfect repeats; total of 96 repeats) in five
FIG. 1. (A and B) Reactivities of sera from guinea pigs and humans with antigens of M. tuberculosis. (A) Western blots of LFCFP (10 g/ml)
were probed with sera from guinea pigs and humans. Lanes 2 and 3 were probed with sera from two uninfected guinea pigs, lanes 4 and 5 with
sera from two M. tuberculosis H37Rv-infected guinea pigs bled at 15 weeks p.i., lanes 6 to 9 with sera from four HIV TB patients, and lanes
10 and 11 with sera from two PPD healthy individuals. Lane 1 contains molecular weight markers in thousands. The major protein bands
recognized by sera from tuberculous guinea pigs and HIV TB patients are indicated by arrows in lane 4. (B) Western blots of LFCFP (10 g/ml)
were probed with sera from guinea pigs. Lanes 1 to 4 were probed with sera from four M. tuberculosis-infected guinea pigs obtained at 1 week p.i.
(1WKPI), lanes 5 to 7 with sera from three animals obtained at 2 weeks p.i., lanes 8 to 12 with sera from five animals obtained at 3 weeks p.i., lanes
13 to 16 with sera from four animals obtained at 4 weeks p.i., lanes 17 to 20 with sera from four animals obtained at 5 weeks p.i., lanes 21 to 24
with sera from four animals obtained at 6 weeks p.i., lanes 25 to 27 with sera from three animals obtained at 10 weeks p.i., lanes 28 and 29 with
sera from two animals obtained at 15 weeks p.i., and lanes 30 to 32 with sera from three uninfected guinea pigs. Lanes M contain molecular weight
markers (in thousands). The positive and negative signs below each lane indicate the reactivities of the respective serum specimens with M.
tuberculosis LFCFP, lysate, SDS-CW, CW, and purified 38-kDa and 45-kDa antigens, as determined by ELISA. The mean OD490 obtained with
sera from uninfected guinea pigs plus 3 SD was used as the cutoff. ND, not done.
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clusters (repetitive clusters [RC]) that show 76 to 81% identity
with each other. The protein has six large hydrophobic regions
alternating with five hydrophilic regions (20), and each of the
five RC overlaps with portions of both the hydrophobic and the
hydrophilic regions (Fig. 2). PPE55 has a signal peptide, a
putative signal peptidase cleavage site between aa 29 and 30,
29 putative transmembrane helices, and 41 putative O-glyco-
sylation sites. The contents of Gly (19.9%), Asn (11.1%), and
hydrophobic amino acids (29.6%, including Leu, Val, Ile, Phe,
and Met) are relatively high.
The N-terminal 180 aa of PPE55 showed 60 to 90% homol-
ogy with the N-terminal amino acids of other PPE proteins in
the M. tuberculosis database. In contrast, the C-terminal region
of PPE55 (2,977 aa) is strongly homologous (67%) to PPE56,
but only small regions of homology are observed with the other
PPE proteins. In the M. bovis isolate that is sequenced, the
homologous gene is split into two parts as a result of a single
base deletion, and the existence of two proteins, PPE55a (2,096
aa) and PPE55b (1,061 aa), is predicted. A BLAST analysis of
the PPE55 N-terminal 180-aa region against the M. leprae and
M. avium subsp. paratuberculosis databases showed 30 to 66%
homology with multiple proteins, while the C-terminal region
showed poor homology in small regions. Similar results were
obtained when a BLAST analysis against the unfinished data-
bases of M. avium 104, M. marinum, M. ulcerans, and M. smeg-
matis was performed.
Distribution of the PPE55 gene in mycobacteria. A BLAST
analysis suggested that no genes that were strongly homolo-
gous to PPE55 were present in the non-TB mycobacterial
species that have been sequenced. To further determine if the
PPE55 gene is specific to M. tuberculosis and to determine if
the gene is conserved between clinical isolates, the distribution
of the PPE55 gene in the M. tuberculosis complex, M. tubercu-
losis clinical isolates, and nontuberculous mycobacterial spe-
cies was determined by Southern blot analysis. The DIG-la-
beled, 480-bp PCR product of primers PPE1 and PPE2, which
was used to probe the Southern blots, hybridized with two
fragments of 23 kb and 8 kb in genomic DNA from all M.
tuberculosis complex species but not with any of the nontuber-
culous mycobacterial species tested (Fig. 3A). When the same
blot was reprobed with a PCR-generated 23S gene probe, all
mycobacterial species showed a hybridization signal (data not
shown). Although primers PPE1 and PPE2 were designed to
amplify a 480-bp fragment only from the PPE55 gene, the
nucleotide sequence of this fragment showed 83% identity with
a 462-bp fragment from PPE56 and 89% identity with a 194-bp
fragment from PPE54. Restriction analysis of the PPE55 gene
and flanking regions showed that the 23-kb fragment con-
tains the portion of the PPE55 gene encompassing the probe
sequence and the complete PPE54 gene. The 8-kb fragment
contains a portion of the PPE56 gene encompassing the region
which is homologous with the probe sequence. Thus, hybrid-
ization with the 23-kb fragment would be due to hybridiza-
tion with the PPE55 gene and cross-hybridization with the
PPE54 gene. The hybridization with the8-kb fragment would
be due to hybridization with the PPE56 gene. The same pat-
tern of hybridization with two bands at 23 kb and 8 kb was
also observed with the genomic DNA from 6 out of 7 clinical
isolates tested (Fig. 3B). The different hybridization pattern
obtained with one clinical isolate (CSU 17) could be due to
changes in the nucleotide sequence of either the PPE55 gene
or the flanking regions and was not investigated further. These
results indicate that the PPE55 gene is specific to M. tubercu-
losis complex species and is present in a majority of the clinical
isolates tested.
Expression of recombinant PPE55 protein and its reactivity
with sera from M. tuberculosis-infected guinea pigs and TB
patients. Since the PPE55 protein was immunogenic in M.
tuberculosis-infected guinea pigs, its immunogenicity in hu-
mans with TB was investigated. Both of the clones (1 and 2)
identified by the guinea pig sera expressed fragments located in
the C-terminal region of the PPE55 protein, suggesting that
this portion of the protein is immunogenic. Since the PPE55
protein is too large to be expressed as one unit, the C-terminal
978 amino acids (PPE-C; 99 kDa) were cloned into pET14b
in frame with the N-terminal His tag (Fig. 2). The PPE-C
protein encompasses the regions that were expressed in clones
1 and 2 and contains the RC5 region of PPE55 (Fig. 2). Lysates
of induced E. coli cells expressing the His-tagged PPE-C pro-
tein contained an 99-kDa protein recognized by anti-His
MAb (Fig. 4A, lane 4). Two other bands (66 kDa and 36
kDa) reactive with anti-His antibody were also present, sug-
gesting that the PPE-C protein may undergo processing/deg-
radation in E. coli. No protein bands that react with anti-His
FIG. 2. Schematic representation of the PPE55 (Rv3347c) protein of M. tuberculosis H37Rv. The dotted areas show hydrophobic regions. The
striped areas indicate the positions of the repetitive clusters (RC1 to RC5). The black bars denote the portions of the PPE55 protein expressed
in gt11 clones 1 and 2 and in the PPE-C protein. The positions of the peptides are indicated by black lines. The arrow indicates the signal
peptidase cleavage site. The conserved N-terminal 180-aa region is marked.
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antibody were detectable in either of the control lysates. The
serum pool used for immunoscreening of the library, but not
the pool from the uninfected guinea pigs, showed strong reac-
tivities with the 99-kDa and 66-kDa bands but not with the
36-kDa band (Fig. 4A, lane 12). These data suggest that
immunogenic regions are present only in the 99-kDa and
66-kDa proteins and also confirm that PPE55 is expressed
during subclinical TB in guinea pigs and that the PPE-C frag-
ment of the PPE55 protein is immunogenic.
To confirm that anti-PPE-C antibodies are detectable in TB
patients, the recombinant protein was purified by Ni-nitrilotri-
acetic acid agarose affinity chromatography. A Western blot of
purified PPE-C protein probed with anti-His MAb confirmed
the presence of the 99-kDa band in the purified protein
preparation (Fig. 4B, lane 2). As was observed with lysates of
E. coli expressing PPE-C protein, some additional protein
bands, probably degradation products of the recombinant pro-
tein, were also present. Western blots of purified PPE-C pro-
tein were probed with sera from four HIV TB patients and
four PPD healthy individuals. Antibodies that recognized the
99-kDa PPE-C protein were present only in the sera from TB
patients and not in the sera from the PPD healthy individuals
tested (Fig. 4B, lanes 3 to 6).
Reactivity of purified PPE-C protein with sera from various
groups of TB patients. After confirmation that anti-PPE-C
antibodies are present in TB patients but not in PPD healthy
individuals, the ability of the protein to distinguish between
patients with active infection and latent or no infection with M.
tuberculosis was determined. The reactivity of the purified
PPE-C protein was evaluated with sera from PPD and PPD
healthy individuals, as well as from patients with subclinical
TB. Sera from patients with clinical TB were also included.
There was no difference in the reactivities of sera obtained
from PPD or PPD healthy individuals, suggesting that an-
tibodies to this protein are absent in healthy individuals with
latent, inactive M. tuberculosis infection or in BCG-vaccinated
individuals (Fig. 5). With the mean OD obtained with the
PPD and PPD healthy individuals plus 3 SD as the cutoff,
none of the sera from these individuals contained anti-PPE-C
antibodies. In contrast, subclinical-TB sera (obtained from 3
months to 2 years prior to manifestation of clinical TB) from
17/21 (81%) HIV TB patients had anti-PPE-C antibodies
(Fig. 5). Sera from 29/30 (97%) HIV TB patients and 17/24
(71%) HIV TB patients also had detectable anti-PPE-C
antibodies (Fig. 5), confirming the correlation of active M.
tuberculosis infection and anti-PPE-C antibodies. Each serum
specimen was tested in three separate ELISA, and only spec-
imens which tested positive three of three or two of three times
were considered positive. No correlation between the presence
or absence of anti-PPE-C antibodies and the AFB smear sta-
tus, radiological features, or lymphocyte profile was observed
FIG. 3. (A and B) Presence of the PPE55 (Rv3347c) gene in dif-
ferent mycobacterial species and M. tuberculosis clinical isolates.
Southern blots of SacI-digested genomic DNA were probed with a
480-bp, DIG-labeled, PCR-generated PPE55 gene fragment. (A) DNA
from M. tuberculosis H37Rv (lane 1), M. tuberculosis H37Ra (lane 2),
M. bovis BCG (lane 3), M. bovis (lane 4), M. africanum (lane 5), M.
microti (lane 6), M. tuberculosis Erdman (lane 7), M. smegmatis (lane
8), M. vaccae (lane 9), M. phlei (lane 10), M. chelonae (lane 11), and M.
xenopi (lane 12). (B) DNA from M. tuberculosis H37Rv (lane 1); M.
tuberculosis clinical isolates CSU 11, CSU 17, CSU 19, CSU 22, CSU
25, CSU 26, and CSU 27 (lanes 2 through 8, respectively); and M.
tuberculosis Erdman (lane 9).
FIG. 4. (A and B) Expression of a recombinant His-tagged, C-
terminal fragment of PPE55 (PPE-C) and its reactivities with guinea
pig and human sera. (A) Western blots of E. coli lysates were probed
with anti-His MAb (lanes 2 to 4), a serum pool from uninfected guinea
pigs (lanes 6 to 8), and a serum pool from M. tuberculosis H37Rv-
infected guinea pigs bled 1 to 6 weeks p.i. (lanes 10 to 12). Lanes 1, 5,
and 9 contain molecular mass markers; lanes 2, 6, and 10 contain
lysates of induced E. coli containing vector alone; lanes 3, 7, and 11
contain lysates of uninduced E. coli containing recombinant plasmid;
and lanes 4, 8, and 12 contain lysates of induced E. coli containing
recombinant plasmid. (B) Western blots of purified PPE-C protein
were probed with anti-His MAb (lane 2), sera from four HIV TB
patients (lanes 3 to 6), or sera from four PPD healthy individuals
(lanes 7 to 10). Lane 1 contains molecular mass markers.
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for the HIV TB patients (Table 1). Anti-PPE-C antibodies
were detected in sera from 10 to 15% of the individuals con-
sidered to be at high risk for TB; 3/20 (15%) HIV TB
individuals and 2/19 (11%) household contacts of smear-posi-
tive patients possessed anti-PPE-C antibodies (Fig. 5).
Reactivities of antigenic peptides of PPE-C protein with
sera from TB patients. Since PPE55 is a member of a protein
family, to determine if the anti-PPE-C antibodies are elicited
by this protein or by other PPE proteins with cross-reactive
regions, efforts to identify PPE55-specific immunogenic re-
gions were made. The analysis by computer algorithms of the
PPE-C amino acid sequence for regions with high antigenicity
identified two immunogenic regions (Fig. 2). Peptides corre-
sponding to both regions (PPE-C1 and PPE-C2) were synthe-
sized commercially. The sequence of PPE-C1 (aa 2180 to 2195;
GSINTGWFNTGNANTG) showed homology with the major-
ity of PPE proteins from the M. tuberculosis H37Rv, M. tuber-
culosis CDC1551, and M. bovis genome databases. This pep-
tide also showed homology with multiple fragments from the
M. tuberculosis 210 and M. marinum unfinished-genome data-
bases. No match was obtained when analyses of the M. leprae
and M. avium subsp. paratuberculosis genomes and of the un-
finished genomes of M. ulcerans, M. smegmatis, and M. avium
104 were performed. In contrast, PPE-C2 (aa 2931 to 2949;
GFKVRPSFSFFAVGPDGMP) was specific to PPE55 and
showed no homology with any other PPE protein or any pro-
tein/region from the M. tuberculosis H37Rv, M. tuberculosis
CDC1551, M. bovis, M. tuberculosis 210, and M. ulcerans data-
bases. Despite the 67% homology of the C-terminal regions of
PPE55 and PPE56, no region homologous to the PPE-C2 pep-
tide was found with the latter. The PPE-C2 sequence showed
weak homology (40%) with two proteins (not PPE proteins)
from the M. leprae genome database. One protein from each of
the M. avium subsp. paratuberculosis, M. marinum, M. avium
104, and M. smegmatis databases also showed 40% homol-
ogy. Thus, while PPE-C1 encompasses a cross-reactive immu-
nogenic region, PPE-C2 appears to be specific to PPE55.
Antibodies to the PPE-C1 peptide were detected in 1/39
(3%) control individuals (97% specificity). In contrast, 6/21
(29%), 11/24 (46%), and 17/30 (57%) serum samples from
HIV subclinical-TB, HIV TB, and HIV TB patients,
respectively, contained anti-PPE-C1 antibodies. Similarly, anti-
PPE-C2 antibodies were detected in only 1/39 (3%) healthy
individuals but in 12/21 (57%), 12/24 (50%), and 16/30 (53%)
FIG. 5. Reactivities of purified PPE-C protein with sera from humans. Serum samples from PPD and PPD healthy individuals; HIV
subclinical-TB, HIV TB, HIV TB, and HIV TB patients; and HIV TB HH contacts were tested by ELISA for reactivity with purified
PPE-C. The mean OD490 obtained with PPD
 and PPD healthy individuals, plus 3 SD, was used as the cutoff. The OD obtained with any serum
specimen minus the cutoff (	 O.D.) for each specimen is plotted. Each line connects the reactivity of serum obtained during subclinical-TB
infection with that of serum obtained at the time of diagnosis of TB from the same HIV TB patient.
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serum samples from HIV subclinical-TB, HIV TB, and
HIV TB patients, respectively (Table 2). Even when addi-
tive reactivities with both peptides were considered, the sensi-
tivities of antibody detection (57%, 63%, and 67% in HIV
subclinical-TB, HIV TB, and HIV TB patients, respec-
tively) were lower than the sensitivity obtained with the PPE-C
protein in each group of patients, indicating that additional
immunogenic regions must exist on the protein (Table 2).
To determine if the anti-PPE-C antibodies are elicited by
the PPE55 protein or another PPE protein(s), the proportion
of patients with anti-PPE-C1 (cross-reactive epitope) or anti-
PPE-C2 (specific epitope) antibodies among patients with
PPE-C antibodies was determined. Of the patients who had
antibodies to the PPE-C protein, anti-PPE-C1 antibodies were
present in 5/11 (45%), 9/12 (75%), and 17/20 (85%) patients,
and anti-PPE-C2 antibodies were present in 11/11 (100%),
10/12 (83%), and 16/20 (80%) patients from the HIV sub-
clinical-TB, HIV TB, and HIV TB patient groups, re-
spectively (Table 2). There was a statistically significant corre-
lation between the presence of antibodies to the two peptides
in the three patient groups (P values were 0.0351, 0.0104, and
0.0086 for patients from the HIV subclinical-TB, HIV TB,
and HIV TB groups, respectively), indicating that the anti-
PPE-C antibodies detected in the patients are elicited by the in
vivo expression of PPE55.
DISCUSSION
The goal of these studies was to identify antigens expressed
by actively replicating in vivo M. tuberculosis during subclinical
stages of TB but not by the latent bacteria. Since humans with
incipient, subclinical TB cannot be recognized, antibodies in
sera from M. tuberculosis aerosol-infected guinea pigs were
used as markers of in vivo-expressed proteins. Several studies
have shown that M. tuberculosis infection in guinea pigs resem-
bles M. tuberculosis infection in humans in the development of
typical mononuclear cell granulomas in the lungs, caseation,
extrapulmonary dissemination, hematogenous reseeding of
apical lobes, and development of the delayed-type-hypersensi-
tivity reaction (26). The use of the guinea pig model for studies
of anti-M. tuberculosis humoral responses was validated in the
current studies by the recognition of similar profiles of antigens
in the LFCFP by antibodies from tuberculous humans and
guinea pigs. Earlier studies have shown that in guinea pigs
TABLE 1. Correlation between AFB smear status, radiological features, lymphocyte profile, and antibodies to PPE-Ce
Disease status
(no. of patients)
AFB smear status
(no. of patients)
Radiological appearance
(no. of patients)
Lymphocyte profile No. (%) of patients
screened for
antibodies to PPE-CAbsolute cell count % Cells
T CD4 CD4 CD8 B Positive Negative
HIV
subclinical
TB (21)
ND ND 225–3,350 9–525 1–23 31–82 1–25 17 (81) 4 (19)
HIV TB
(24)a
Positive (16) Cav. (2)d; non-cav. (14)b 155–3,962 7–552 1–29 24–71 3–29 13 (81)d 3 (19)
Negative (7) Cav. (0); non-cav. (7)c 467–1,309 71–332 9–22 46–70 2–19 3 (43) 4 (57)
HIV TB (20) ND ND 641–2,698 108–862 8–54 19–72 3–27 3 (15) 17 (85)
HIV TB (30) Positive (30) Cav. (30); non-cav. (0) ND ND ND ND ND 29 (97) 1 (3)
HIV TB HH
contact (19)
ND ND ND ND ND ND ND 2 (11) 17 (89)
a For one patient, AFB smear and radiographic results were not available.
b Eight patients had infiltration, one had patchy areas, one had pleural effusion, and four showed no pulmonary changes.
c One patient had infiltration, one had patchy areas, and five showed no pulmonary changes.
d Both cavitary-TB patients were positive for antibodies to PPE-C.
e ND, not done; cav., cavitary TB; non-cav., non-cavitary TB.
TABLE 2. Reactivities of antigenic peptides of PPE-C with sera from TB patientsa
Disease status
(no. of patients)
No. (%) of patients with antibodies to:
No. (%) of PPE-C antibody-
positive patients with antibodies
to:
P valueb
PPE-C
protein
PPE-C1
peptide
PPE-C2
peptide
PPE-C1 and/or
PPE-C2
peptides
PPE-C1 and/or
PPE-C2
peptides
PPE-C1
peptide
PPE-C2
peptide
HIV subclinical TB (21) 17 (81) 6 (29) 12 (57) 12 (57) 11 (65) 5 (45) 11 (100) 0.0351
HIV TB(24) 17 (71) 11 (46) 12 (50) 15 (63) 12 (71) 9 (75) 10 (83) 0.0104
HIV TB (30) 29 (97) 17 (57) 16 (53) 20 (67) 20 (69) 17 (85) 16 (80) 0.0086
a The presence of antibodies to PPE-C and peptides PPE-C1 and PPE-C2 in sera from TB patients and PPD/PPD healthy controls was determined by ELISA.
The mean OD plus 3 SD obtained with healthy controls was used as the cutoff to determine positive responses in patients.
b Correlation between the presence of antibodies to PPE-C1 and PPE-C2, as determined by the Fisher test.
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infected with a low dose (4 to 10 CFU) of M. tuberculosis, the
inhaled mycobacteria replicate exponentially in the lungs dur-
ing the first 3 to 4 weeks p.i. Dissemination via the lymphatics
to the lymph nodes draining the lungs occurs at about 8 to 10
days p.i., with organisms reaching the spleen via the blood-
stream between 14 and 20 days. Within 4 weeks following
initiation of pulmonary infection, there is seeding of mycobac-
teria into secondary foci throughout the lungs via hematoge-
nous dissemination (15, 28). The clinical signs of TB, such as
weight loss and respiratory distress, usually occur around 8 to
10 weeks p.i., and mortality is generally observed around 14 to
18 weeks (27). Based on these well-defined kinetics of infec-
tion, the period of 1 to 6 weeks p.i. for these animals corre-
sponds to the stage when they have incipient, subclinical TB
but have not yet progressed to clinically evident TB.
The antibodies in the guinea pig subclinical-TB serum pool
identified PPE55 as one of the proteins expressed during in-
cipient M. tuberculosis infection. The characteristics of PPE55
(signal sequence and transmembrane regions) indicate that
PPE55 should be a cell surface-associated or -secreted protein.
However, no protein of this size was detectable by Western
blot analysis of the LFCFP (Fig. 1B) or the SDS-CW prepa-
rations (data not shown). These results indirectly suggest that
PPE55 is either poorly expressed during growth in bacterio-
logical media or degraded during preparation of the mycobac-
terial-antigen fractions. Two other PPE proteins, PPE34
(Rv1917c) and PPE68 (Rv3873), have also been shown to be
cell surface associated, and the latter protein has been re-
ported to be quantitatively a minor component in preparations
derived from in vitro-grown bacteria (8, 31, 39). Moreover,
proteomic studies of M. tuberculosis have rarely identified any
PPE proteins as dominant components in preparations made
from M. tuberculosis grown in bacteriological media, suggesting
poor expression in this environment (2, 19, 34, 40).
The recognition of the PPE-C protein by sera obtained dur-
ing subclinical-TB infection from HIV TB patients provides
evidence that it is also expressed at this stage of infection in
humans. Moreover, the absence of anti-PPE-C antibodies in
PPD individuals shows that anti-PPE-C antibodies may be
useful as markers that can discriminate between latent and
incipient infection with M. tuberculosis, especially since PPE55
appears to be restricted to the M. tuberculosis complex. This is
important since no clinical, bacteriological, or radiological
markers for distinguishing between these patients, who are
clinically asymptomatic, are currently available. Earlier studies
of the reactivities of culture filtrate proteins of M. tuberculosis
with multiple serial subclinical-TB sera from the same HIV
TB patients provided evidence for the sustained detection of
antimycobacterial antibodies in specimens obtained over sev-
eral months prior to the clinical presentation of TB (22). Fu-
ture studies of the kinetics of appearance of anti-PPE-C anti-
bodies and their titers will provide additional information on
the practical utility of these antibodies as markers for subclin-
ical TB.
Antibodies to the PPE-C protein were detectable in 81% of
the smear-positive HIV TB patients and 97% of the smear-
positive HIV TB patients but in only 40% of the smear-
negative HIV TB patients. Although this suggests that an-
tibodies are elicited when the disease is advanced and the
bacterial load is high, the presence of antibodies in 81% of the
subclinical-TB sera contradicts this assertion (Table 1). The
smear-negative patient group comprised only seven individu-
als; additional patients need to be evaluated before the actual
sensitivity for this group can be determined. The presence of
anti-PPE-C antibodies in patients with subclinical and clinical
TB suggests that the protein should be useful for identifying all
stages of an active infection. Recognition by both HIV TB
and HIV TB patients is an added advantage, since other
antigens, like the 38-kDa (PstS) protein and antigen 85B, are
poorly immunogenic in HIV patients (25, 48). The presence
of anti-PPE-C antibodies in both cavitary-TB and noncavi-
tary-TB patients provides evidence that, unlike some other
proteins (e.g., the 38-kDa protein) which are expressed pri-
marily during replication in cavitary lesions, PPE55 is ex-
pressed by in vivo bacteria during growth in cavitary as well as
noncavitary environments (Table 1) (4, 35). This is further
emphasized by the finding that anti-PPE-C antibodies are
present in the retrospective, subclinical-TB sera obtained
months before clinical TB was identified. Also, recognition of
PPE-C by a majority of the TB patients from India and the
United States confirms its expression by clinical isolates from
different geographical locations. The ability of the PPE-C pro-
tein, which encompasses only about one-third of the PPE55
protein, to identify 70 to 95% of HIV TB or HIV TB
patients reflects the strong immunogenicity of this protein.
Whether inclusion of the remaining portions of the PPE55
protein will further enhance the sensitivity of detection of
antibodies in TB patients is being investigated.
It has been speculated that the PPE protein family contrib-
utes to antigenic variation in M. tuberculosis. It is not known if
different clinical isolates of M. tuberculosis express the same
PPE protein(s) in vivo and if the same PPE protein(s) is ex-
pressed at different stages of infection. While the entire C-
terminal region of PPE55 (2,977 aa) shows strong homology
only to PPE56, the PPE-C protein (978 aa) shows 42 to 69%
homology with three PPE proteins (PPE34, -54, and -56) and

30% homology in small regions with large gaps with some
other PPE proteins. Thus, it is possible that the anti-PPE-C
antibodies were in fact elicited by other PPE proteins with
cross-reactive epitopes. The prediction of two antigenic re-
gions in the PPE-C protein, one of which is conserved between
several PPE proteins and the other of which is specific to
PPE55, provided the opportunity to determine if the anti-
PPE-C antibodies were in fact elicited by the PPE55 protein.
The strong correlation between the presence of anti-PPE-C1
and anti-PPE-C2 antibodies and the recognition of PPE-C2 by
80 to 100% of the patients who had detectable antipeptide
antibodies indicates that PPE55 is a dominant PPE protein
which is expressed by a large proportion of the M. tuberculosis
isolates only during active infection in humans (Table 2). The
delayed appearance of anti-PPE-C1 antibodies suggests that
the specific epitope may be recognized earlier during the
course of active infection.
Other PPE proteins have been reported to be strongly im-
munogenic (5, 8, 9, 31, 46). Antibodies against PPE41
(Rv2430c) are present in TB patients and not in healthy indi-
viduals (5); PPE68 (Rv3873) induces gamma interferon pro-
duction from splenocytes of M. tuberculosis-infected mice and
from peripheral blood mononuclear cells of TB patients and
PPD healthy individuals (8, 31). Immune responses elicited
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by PPE18 (Rv1196) and PPE14 (Rv0915c) have been shown to
provide some protection in mice infected with M. tuberculosis
(9, 46). Together, these studies suggest that several PPE pro-
teins are expressed in vivo.
Immune responses to ESAT-6 and CFP10 can distinguish
between infection with M. tuberculosis and BCG vaccination;
this is useful in countries where TB control programs are able
to provide preventive therapy to M. tuberculosis-infected indi-
viduals (1, 50). In contrast, the ability of PPE-C (and its pep-
tides) to distinguish between latent TB and incipient, subclin-
ical TB would be of value in countries of TB endemicity where
TB control is focused on detection and treatment only of
patients with active TB. Preventive therapy with isoniazid has
been shown to be beneficial in reducing the incidence of TB in
both HIV and HIV individuals and is especially recom-
mended for HIV individuals (13, 18). However, monotherapy
in individuals with active TB runs the risk of fostering drug
resistance (30), and no reliable tests that can differentiate
between a truly latent infection and incipient, subclinical TB
are available. The presence of anti-PPE-C antibodies in the
retrospective sera from HIV TB individuals and their ab-
sence in a vast majority of the HIV TB patients on antiret-
roviral therapy indicate the potential of PPE-C to act as a
marker for identification of HIV individuals with incipient,
subclinical TB.
Anti-PPE-C antibodies were also detected in 11% of the
household contacts of untreated, infectious TB patients. Inter-
estingly, 6 to 29% of the household contacts of TB patients
were estimated to be at risk of developing TB within 6 months
to 2 years of infection (6, 10, 14, 51). Longitudinal studies with
cohorts comprised of high-risk individuals like the household
contacts of infectious smear-positive TB patients are planned
to determine if the presence of anti-PPE-C antibodies in these
individuals can identify M. tuberculosis-infected HIV individ-
uals who have active but subclinical infection with M. tubercu-
losis and are likely to progress to clinical TB.
Recent studies have suggested that high gamma interferon
production induced by ESAT-6 in household contacts of infec-
tious TB patients may correlate with a high risk of progression
to clinical TB (10). Our earlier studies have shown that anti-
bodies to the malate synthase (Rv1837c) and MPT51
(Rv3803c) proteins of M. tuberculosis are detectable in the
retrospective sera from a majority of HIV TB patients (43).
Antibodies against some M. tuberculosis proteins have also
been shown to be present in sera obtained from M. tuberculosis
H37Rv aerosol-infected rabbits with subclinical TB (45). To-
gether, these results provide evidence that a selected subset of
M. tuberculosis proteins is expressed in vivo and elicits immune
responses months before the infection progresses to symptom-
atic, bacteriologically detectable TB. Further studies with these
antigens will enable a definition of their role in the pathogen-
esis of active infection with M. tuberculosis.
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